In recent years, the intricate world of non-coding RNAs has captivated the scientific community, unveiling unexpected layers of gene regulation and therapeutic potential. Among these regulatory molecules, circular RNAs (circRNAs) have emerged as pivotal players, weaving complex regulatory networks that influence cellular behavior in profound ways. A groundbreaking study by Z. Tajik and S. Ghafouri-Fard, published in Medical Oncology, sheds critical light on the role of circRNAs in modulating the response and resistance to oxaliplatin, a cornerstone platinum-based chemotherapeutic agent widely used in cancer therapy.
Oxaliplatin has long been a frontline weapon in combating colorectal cancer and various other malignancies. Despite its efficacy, resistance to oxaliplatin remains a formidable barrier, often leading to treatment failure and disease progression. Understanding the molecular underpinnings of this resistance is paramount for improving clinical outcomes. Tajik and Ghafouri-Fard’s investigation delineates how circRNAs intricately regulate cellular pathways that govern oxaliplatin sensitivity, charting new territories in cancer therapeutics.
CircRNAs are distinctive in their covalently closed loop structures, which confer exceptional stability compared to linear RNAs. This unique topology protects them from exonuclease-mediated degradation, allowing them to accumulate and exert sustained regulatory effects. The researchers delve into how this stability enables circRNAs to sponge microRNAs (miRNAs), interact with RNA binding proteins, and modulate transcriptional and post-transcriptional landscapes, ultimately influencing how cancer cells respond to chemotherapy.
One of the pivotal revelations from the study lies in the identification of specific circRNAs that act as molecular switches toggling oxaliplatin resistance. These circRNAs function predominantly as competing endogenous RNAs (ceRNAs) by sequestering miRNAs that would otherwise inhibit key oncogenes or drug resistance-associated genes. For instance, the circRNA-mediated sponging of tumor-suppressive miRNAs can alleviate repression on DNA repair genes, thus facilitating cancer cell survival during oxaliplatin-induced DNA damage.
Furthermore, the authors illuminate the bidirectional relationship between circRNAs and signaling pathways implicated in drug resistance. CircRNAs have been shown to modulate pathways such as Wnt/β-catenin, PI3K/Akt, and NF-κB, which confer survival advantages and attenuate apoptotic responses under chemotherapeutic stress. By fine-tuning these signaling cascades, circRNAs sculpt cellular landscapes that favor resistance phenotypes.
Importantly, the study underscores that circRNAs are not mere bystanders but active participants in the epigenetic remodeling that accompanies oxaliplatin resistance. They contribute to the reprogramming of chromatin states and transcriptional machinery through interactions with chromatin modifiers and transcription factors, thereby promoting gene expression patterns that support drug tolerance.
The therapeutic implications are profound. Targeting circRNAs or their interaction networks could restore oxaliplatin sensitivity and circumvent resistance. The study discusses innovative strategies like antisense oligonucleotides (ASOs) and CRISPR/Cas-mediated approaches that selectively degrade or alter circRNAs, offering precision intervention points. Additionally, circRNAs themselves may serve as prognostic biomarkers to predict patient responsiveness to oxaliplatin-based treatment regimens, enabling personalized medicine.
Intriguingly, circRNAs also modulate immune responses within the tumor microenvironment, which can indirectly influence chemotherapy efficacy. By regulating immune checkpoints and cytokine milieus, circRNAs may dictate the balance between immune surveillance and evasion, thus intersecting with immunotherapeutic strategies.
This research opens new avenues for combinatorial therapies. By integrating circRNA-targeting modalities with conventional oxaliplatin chemotherapy or emerging immunotherapies, clinicians may surmount resistance barriers, leading to more durable remissions. The exploitation of circRNA pathways offers a dual advantage: enhancing drug efficacy while minimizing off-target toxicities through specific molecular targeting.
Nevertheless, challenges persist in translating these molecular insights into clinical practice. The complexity of circRNA expression profiles across tumor types, heterogeneity among patients, and the dynamic nature of RNA interactions necessitate comprehensive profiling and longitudinal studies. Moreover, efficient delivery systems for circRNA-targeted therapeutics remain a crucial area for technological advancement.
Despite these hurdles, the revelation of circRNAs as master regulators of oxaliplatin response embodies a paradigm shift. It underscores the necessity of exploring non-coding RNA territories to unravel resistance mechanisms that have remained elusive for decades. The fundamental knowledge garnered not only deepens our understanding of cancer biology but also propels the development of next-generation therapeutics with the potential to redefine cancer treatment landscapes.
From a broader perspective, the study exemplifies the evolving narrative of precision oncology, where molecular intricacies guide tailored treatment decisions. CircRNAs offer a tantalizing glimpse into the molecular dark matter of the genome, turning what was once considered “junk” RNA into a treasure trove of therapeutic targets.
Future investigations will likely focus on expanding the catalog of circRNAs involved in drug resistance, unraveling their tissue-specific roles, and elucidating their interactions within larger regulatory networks. High-throughput sequencing combined with sophisticated bioinformatics will accelerate discoveries, while functional validation in preclinical models will pave the way for clinical translation.
In conclusion, Tajik and Ghafouri-Fard’s seminal work affirms the critical regulatory capacity of circRNAs in oxaliplatin response and resistance, positioning these non-coding RNAs at the forefront of cancer research and therapy innovation. As the fight against chemoresistant cancers intensifies, circRNAs stand out as promising allies, offering hope for more effective, personalized, and durable treatment outcomes.
Subject of Research: Circular RNAs as regulators of oxaliplatin response and resistance in cancer therapy
Article Title: Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy
Article References:
Tajik, Z., Ghafouri-Fard, S. Circular RNAs: emerging regulators of oxaliplatin response and resistance in cancer therapy.
Med Oncol 43, 38 (2026). https://doi.org/10.1007/s12032-025-03171-9
Image Credits: AI Generated
DOI: https://doi.org/10.1007/s12032-025-03171-9
Tags: cancer therapeutics and resistancecircRNAs and microRNA interactionscircular RNAs in cancer therapycolorectal cancer treatment challengesgene regulation by non-coding RNAsmolecular pathways in cancer resistancenon-coding RNAs in gene regulationoxaliplatin as a chemotherapeutic agentoxaliplatin resistance mechanismsstability of circular RNAstherapeutic potential of circRNAsZ. Tajik and S. Ghafouri-Fard research findings
